Remove Drug Development Remove Immunity Remove Magazine
article thumbnail

Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

Pharma Mirror

In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex (KOSDAQ:263050). We are extremely glad to.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. George Underwood is the editor for pharmaphorum’s Deep Dive digital magazine. Chemotherapy still accounted for 72.6% of the oncology market in China in 2019, compared to 17.1%

article thumbnail

A history of the pharmaceutical industry

pharmaphorum

George Merck on the cover of Time magazine. Thalidomide and the development of drug safety regulation and monitoring. Fordian methods enabled more rational methods of mass production, and increasing understanding of biology and chemistry enabled drug candidates to be chosen systematically rather than discovered serendipitously.

Diabetes 145